Fmoc-Val-Cit-PAB-MMAE

CAS No. 1350456-56-2

Fmoc-Val-Cit-PAB-MMAE ( —— )

Catalog No. M23511 CAS No. 1350456-56-2

Fmoc-Val-Cit-PAB-MMAE consists the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Fmoc-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 138 In Stock
10MG 222 In Stock
25MG 401 In Stock
50MG 593 In Stock
100MG 844 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Fmoc-Val-Cit-PAB-MMAE
  • Note
    Research use only, not for human use.
  • Brief Description
    Fmoc-Val-Cit-PAB-MMAE consists the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Fmoc-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC.
  • Description
    Fmoc-Val-Cit-PAB-MMAE consists the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Fmoc-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC.
  • Synonyms
    ——
  • Pathway
    PROTACs
  • Target
    PROTAC
  • Recptor
    Auristatin
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1350456-56-2
  • Formula Weight
    1345.7
  • Molecular Formula
    C73H104N10O14
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:30 mg/mL (22.29 mM)
  • SMILES
    CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@@H](C)C(=O)N[C@H](C)[C@H](C2=CC=CC=C2)O)OC)OC)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(C)C(=O)OCC3=CC=C(C=C3)NC(=O)[C@H](CCCNC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)OCC4C5=CC=CC=C5C6=CC=CC=C46
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • BI-3663

    BI-3663 (BI 3663) is a cereblon-based degrader (PROTAC) of Focal adhesion tyrosine kinase (PTK2/FAK) with a median DC50 of 30 nM to >80% across a panel of eleven HCC cell lines.

  • MS4078

    MS4078 is a novel PROTAC (degrader) of ALK, potently decreases cellular levels of oncogenic active ALK fusion proteins in a concentration- and time-dependent manner in SU-DHL-1 lymphoma and NCI-H2228 lung cancer cells (DC50=11 nM).

  • JQ1-VHL-PROTAC

    JQ1-VHL-PROTAC is a novel PROTAC synthesis.